{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:27:45Z","timestamp":1790681265248,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","internationaljournalofcardiology.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.ijcard.2016.10.084","type":"journal-article","created":{"date-parts":[[2016,10,29]],"date-time":"2016-10-29T18:01:06Z","timestamp":1477764066000},"page":"644-649","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":119,"special_numbering":"C","title":["Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study"],"prefix":"10.1016","volume":"227","author":[{"given":"Eliano P.","family":"Navarese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michalina","family":"Kolodziejczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max-Paul","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Alimohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene M.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Buffon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory YH","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta M.","family":"Siller-Matula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2016.10.084_bb0005","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/CRD.0000000000000034","article-title":"Prognostic role of platelet reactivity in patients with acute coronary syndromes","volume":"22","author":"Cavallari","year":"2014","journal-title":"Cardiol. Rev."},{"key":"10.1016\/j.ijcard.2016.10.084_bb0010","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1161\/CIRCULATIONAHA.108.812636","article-title":"Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up","volume":"119","author":"Marcucci","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.10.084_bb0015","article-title":"Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials","volume":"350","author":"Navarese","year":"2015","journal-title":"Br. Med. J. (Clin. Res. Ed.)"},{"key":"10.1016\/j.ijcard.2016.10.084_bb0020","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.vph.2016.01.003","article-title":"Distribution of clinical events across platelet aggregation values in all-comers treated with prasugrel and ticagrelor","volume":"79","author":"Siller-Matula","year":"2016","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.ijcard.2016.10.084_bb0025","first-page":"600","article-title":"Proprotein Convertase Subtilisin\/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome: A Narrative Review. Annals of Internal Medicine","volume":"164","author":"Navarese","year":"2016","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.ijcard.2016.10.084_bb0035","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1161\/CIR.0b013e31826e1058","article-title":"Third universal definition of myocardial infarction","volume":"126","author":"Thygesen","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.10.084_bb0040","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.10.084_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146920","article-title":"PCSK9 plasma concentrations are independent of GFR and do not predict cardiovascular events in patients with decreased GFR","volume":"11","author":"Rogacev","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ijcard.2016.10.084_bb0050","series-title":"Applied Logistic Regression","author":"Hosmer","year":"2013"},{"key":"10.1016\/j.ijcard.2016.10.084_bb0055","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/eurheartj\/ehs233","article-title":"Positive association of serum prolactin concentrations with all-cause and cardiovascular mortality","volume":"35","author":"Haring","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2016.10.084_bb0060","first-page":"580","article-title":"Time course of events in acute coronary syndromes: implications for clinical practice from the GRACE registry. Nature clinical practice","volume":"5","author":"Fox","year":"2008","journal-title":"Cardiovasc. Med."},{"key":"10.1016\/j.ijcard.2016.10.084_bb0065","doi-asserted-by":"crossref","first-page":"261","DOI":"10.7326\/0003-4819-158-4-201302190-00006","article-title":"Optimal timing of coronary invasive strategy in non-ST-segment elevation acute coronary syndromes: a systematic review and meta-analysis","volume":"158","author":"Navarese","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ijcard.2016.10.084_bb0070","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1161\/CIRCRESAHA.115.307016","article-title":"Platelet-mediated thrombosis: from bench to bedside","volume":"118","author":"Gurbel","year":"2016","journal-title":"Circ. Res."},{"key":"10.1016\/j.ijcard.2016.10.084_bb0075","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1161\/01.CIR.0000130846.46168.03","article-title":"Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction","volume":"109","author":"Matetzky","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.10.084_bb0080","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1538-7836.2012.04639.x","article-title":"Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study","volume":"10","author":"Siller-Matula","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2016.10.084_bb0085","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1056\/NEJMe038191","article-title":"Antiplatelet therapy for ischemic heart disease","volume":"350","author":"Lange","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2016.10.084_bb0090","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ahj.2006.04.012","volume":"152","author":"Wiviott","year":"2006","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2016.10.084_bb0095","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2016.10.084_bb0100","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/eurheartj\/ehv637","article-title":"Prognostic value of PCSK9 levels in patients with acute coronary syndromes","volume":"37","author":"Gencer","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2016.10.084_bb0105","series-title":"Coronary Artery Disease: From Atherosclerosis to Cardiogenic Shock","first-page":"221","article-title":"PCSK9 in relation to coronary plaque inflammation and cardiovascular outcome","author":"Cheng","year":"2015"},{"key":"10.1016\/j.ijcard.2016.10.084_bb0110","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/j.ijcard.2012.05.040","article-title":"Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study","volume":"167","author":"Siller-Matula","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2016.10.084_bb0115","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2016.10.084_bb0120","first-page":"e344","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines","volume":"130","author":"Amsterdam","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.10.084_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/0021-9150(93)90035-S","article-title":"Increased platelet-fibrinogen interaction in patients with hypercholesterolemia and hypertriglyceridemia","volume":"103","author":"Pawlowska","year":"1993","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijcard.2016.10.084_bb0130","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/09537109709169333","article-title":"Differential effects of native and oxidatively modified low-density lipoproteins on platelet function","volume":"8","author":"Naseem","year":"1997","journal-title":"Platelets"},{"key":"10.1016\/j.ijcard.2016.10.084_bb0135","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/nm1626","article-title":"Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype","volume":"13","author":"Podrez","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.ijcard.2016.10.084_bb0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106294","article-title":"Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies","volume":"9","author":"Almontashiri","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ijcard.2016.10.084_bb0145","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/1471-2261-14-192","article-title":"Proprotein convertase subtilisin\/kexin type 9 expression is transiently up-regulated in the acute period of myocardial infarction in rat","volume":"14","author":"Zhang","year":"2014","journal-title":"BMC Cardiovasc. Disord."},{"key":"10.1016\/j.ijcard.2016.10.084_bb0150","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.atherosclerosis.2016.02.011","article-title":"Role of PCSK9 antibodies in cardiovascular disease: critical considerations of mortality and neurocognitive findings from the current literature","volume":"247","author":"Kolodziejczak","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijcard.2016.10.084_bb0155","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/ehjcvp\/pvv045","article-title":"From proprotein convertase subtilisin\/kexin type 9 to its inhibition: state-of-the-art and clinical implications","volume":"2","author":"Navarese","year":"2016","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"10.1016\/j.ijcard.2016.10.084_bb0160","doi-asserted-by":"crossref","first-page":"40","DOI":"10.7326\/M14-2957","article-title":"Effects of proprotein convertase subtilisin\/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis","volume":"163","author":"Navarese","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ijcard.2016.10.084_bb0165","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2016.10.084_bb0170","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1161\/01.ATV.0000134621.14315.43","article-title":"Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia","volume":"24","author":"Dubuc","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527316332727?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527316332727?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,27]],"date-time":"2019-04-27T09:26:10Z","timestamp":1556357170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527316332727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":33,"alternative-id":["S0167527316332727"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2016.10.084","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2016.10.084","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}